Suppr超能文献

用屈大麻酚治疗慢性顽固性神经性疼痛:两名青少年的病例报告

Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents.

作者信息

Rudich Zvia, Stinson Jennifer, Jeavons Michael, Brown Stephen C

机构信息

Department of Anasthesia, The Hospital for Sick Children, University of Toronto, Canada.

出版信息

Pain Res Manag. 2003 Winter;8(4):221-4. doi: 10.1155/2003/675976.

Abstract

OBJECTIVE

To evaluate the effectiveness of dronabinol for the treatment of neuropathic pain refractory to previous treatment.

METHODS

We studied the response (reduction of pain intensity and functional improvement) to dronabinol (5 mg/day to 25 mg/day) in two adolescents with neuropathic pain and depression refractory to previous treatments over two and five years, respectively.

RESULTS

Reduction in pain intensity (45%) was achieved in patient 2 and was unchanged in patient 1. Functional improvement was markedly increased in terms of academic performance, mood and sleep in both patients over four to five months, without major adverse effects. While these improvements dissipated over time, the patients were more reconnected with rehabilitation and focused less on the intrusiveness of their pain problem in their every day lives.

CONCLUSIONS

Dronabinol appeared to be effective in improving pain affect and psychosocial functioning in the treatment of refractory neuropathic pain and may be considered as an adjuvant medication in the rehabilitation process. Well-controlled placebo studies are required for further evaluation.

摘要

目的

评估屈大麻酚对先前治疗难治的神经性疼痛的治疗效果。

方法

我们分别研究了两名患有神经性疼痛和抑郁症且对先前治疗无效的青少年患者,在两年和五年时间里对屈大麻酚(5毫克/天至25毫克/天)的反应(疼痛强度降低和功能改善)。

结果

患者2的疼痛强度降低了45%,患者1的疼痛强度没有变化。在四到五个月的时间里,两名患者在学业成绩、情绪和睡眠方面的功能均有显著改善,且无重大不良反应。虽然这些改善随着时间的推移而消失,但患者与康复的联系更加紧密,并且在日常生活中对疼痛问题的困扰关注较少。

结论

屈大麻酚在治疗难治性神经性疼痛中似乎对改善疼痛影响和心理社会功能有效,可被视为康复过程中的辅助药物。需要进行严格对照的安慰剂研究以作进一步评估。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验